Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7219-7229

  Sun, Lian Qi ^a   Zhu, Lei ^b   Qian, Keduo ^c   Qin, Bingjie ^a   Huang, Li ^b   Chen, Chin Ho ^b   Lee, Kuo Hsiung ^c,d   Xie, Lan ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University of North Carolina   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 N (4' CYANOPHENYL) 5 (4 '' CYANOVINYL 2'',6'' DIMETHYLPHENOXY) 4 HYDROXYMETHYLBENZENE 1,2 DIAMINE; 4 CARBAMOYL 1 N (4' CYANOPHENYL) 5 (4'' CYANOVINYL 2'',6'' DIMETHYLPHENOXY)BENZENE 1,2 DIAMINE; 5 (4'' CYANOETHYL 2'',6'' DIMETHYLPHENOXY) 1 N (4' CYANOPHENYL) 4 HYDROXYMETHYLBENZENE 1,2 DIAMINE; ANILINE DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; VIRUS STRAIN;

ANILINE COMPOUNDS; ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROSOMES, LIVER; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84866918553     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3007678     Document Type: Article

References (17)

1. Fauci, A. S. AIDS: let science inform policy. Science 2011, 333 (6038), 13.
2. Shattock, R. J.; Warren, M.; McCormack, S.; Hankins, C. Turning the tide against HIV. Science 2011, 333 (6038), 42-43.
3. Kaufmann, G. R.; Cooper, D. A. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr. Opin. Microbiol. 2000, 3, 508-514.
4. Vella, S.; Palmisano, L. Antiretroviral therapy: state of the HAART. Antiviral Res. 2000, 45, 1-7.
5. Pecora Fulco, P.; McNicholl, I. R. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009, 29 (3), 281-294.
6. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33, 307-320.
7. Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak, M. A.; Hughes, S. H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385, 693-713.
8. Vingerhoets, J.; Azijn, H.; Fransen, E.; De Baere, I.; Smeulders, L.; Jochmans, D.; Andries, K.; Pauwels, R.; de Bethune, M. P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 2005, 79, 12773-12782.
9. Qin, B. J.; Jiang, X. K.; Lu, H.; Tian, X. T.; Barbault, F.; Huang, L.; Qian, K.; Chen, C. H.; Huang, R.; Jiang, S.; Lee, K. H.; Xie, L. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2010, 53, 4906-4916.
10. Tian, X, T.; Qin, B. J.; Wu, Z. Y.; Wang, X. F.; Lu, H.; Morris-Natschke, S. L.; Chen, C. H.; Jiang, S.; Lee, K. H.; Xie, L. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 2010, 53, 8287-8297.
11. De Corte, B. L. From 4, 5, 6, 7-tetrahydro-5-methylimidazo[4, 5, 1-jk](1, 4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 2005, 48, 1689-1696.
12. Piersanti, G.; Giorgi, L.; Bartoccini, F.; Tarzia, G.; Minetti, P.; Gallo, G.; Giorgi, F.; Castorina, M.; Ghirardi, O.; Carminati, P. Synthesis of benzo[1, 2-d;3, 4-d′] diimidazole and 1H-pyrazolo[4, 3-b]pyridine as putative A2A receptor antagonists. Org. Biomol. Chem. 2007, 5, 2567-2571.
13. Azijn, H.; Tirry, I.; Vingerhoets, de Bethune, J.; M., P.; Kraus, G.; Boven, K.; Jochmans, D.; Craenenbroeck, E. V.; Picchio, G.; Rimsky, L. T. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 2010, 54, 718-727.
14. Janssen, P. A.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 2005, 48, 1901-1909.
15. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
16. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization; Academic Press: Boston, MA, 2008; p 65.
17. Dang, Z.; Lai, W.; Qian, K.; Lee, K. H; Chen, C. H.; Huang, L. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. J. Med. Chem. 2009, 52, 7887-7891.